10.29.26 -- Regulators Tighten Scrutiny While Too Many Vendors Strain Study Execution

FDA's July 2026 final guidance on psychedelic drug clinical investigations sets expectations for sponsors developing psilocybin, LSD, and MDMA therapies. Learn what it means for your program.

A new study finds fewer than half of EU Clinical Trial Information System (CTIS) trials met results reporting requirements. The EMA is now watching more closely. Here’s what sponsors need to know.

Quickly assess clinical trial risks by evaluating site impact, patient safety, and budget tradeoffs. Turn high-pressure rescue scenarios into clear, actionable paths for your research team.

Learn how structured oversight, transparency, and collaboration help ensure compliance, reduce bias, and build trust while enabling innovation in increasingly data-driven trials.

By supporting the development and validation of fit-for-purpose, patient-centered digital measures, this framework helps transform RWD into validated clinical evidence across clinical research programs.

Despite resource concerns, FDA is still meeting timelines. See real examples, meeting types, and the prep habits that turn agency interactions into clear next steps.

Discover how hidden operational uncertainties trigger defensive pricing and scope disputes—and how early transparency builds stable, high-performing research partnerships.

Operational friction can hinder trial performance. Discover how centralizing key functions improves coordination, lowers administrative burden, and enhances stakeholder experiences.

Leveraging our extensive expertise across over 120 therapeutic indications, we help biotech sponsors start trials faster, avoid costly missteps, and move promising therapies closer to patients.